TCM
MRNA icon

Twin Capital Management’s Moderna MRNA Stock Holding History

Twin Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-11,952
Closed -$1.41M – 303
2022
Q3 		$1.41M Sell
11,952
-75
-0.6% -$11.4K 0.19% 148
2022
Q2 		$1.72M Sell
12,027
-287
-2% -$41K 0.22% 136
2022
Q1 		$2.12M Sell
12,314
-76
-0.6% -$12.8K 0.23% 134
2021
Q4 		$3.15M Sell
12,390
-230
-2% -$67.2K 0.31% 108
2021
Q3 		$4.86M Sell
12,620
-426
-3% -$157K 0.5% 50
2021
Q2 		$3.07M Sell
13,046
-5,686
-30% -$1.02M 0.28% 117
2021
Q1 		$2.45M Sell
18,732
-1,900
-9% -$275K 0.24% 131
2020
Q4 		$2.15M Sell
20,632
-3,543
-15% -$358K 0.2% 139
2020
Q3 		$1.71M Sell
24,175
-195
-0.8% -$13.6K 0.15% 161
2020
Q2 		$1.56M Buy
+24,370
New +$1.33M 0.15% 172

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Twin Capital Management's MRNA Position: Q4 2022 in Review

Twin Capital Management sold out of Moderna (MRNA) in Q4 2022, closing a stake of 11,952 shares — an estimated $1.41M sold.

Twin Capital Management first reported a position in MRNA in Q2 2020 and held it in 10 quarters. The position peaked at $4.86M in Q3 2021. 1,071 funds tracked by Wall St. Rank hold MRNA as of Q4 2022.

  • Twin Capital Management reported no remaining Moderna position as of Q4 2022 after selling out during the quarter.
  • Twin Capital Management sold 11,952 Moderna shares in Q4 2022, an estimated $1.41M.
  • Twin Capital Management first reported a position in Moderna in Q2 2020 and held it in 10 quarters.
  • Twin Capital Management's Moderna position peaked at $4.86M in Q3 2021.
  • 1,071 funds tracked by Wall St. Rank held Moderna as of Q4 2022.

Based on Twin Capital Management's 13F filing for Q4 2022, filed 31 Jan 2023.